Corvus Pharmaceuticals Inc (NASDAQ: CRVS) on Friday, soared 4.36% from the previous trading day, before settling in for the closing price of $4.13. Within the past 52 weeks, CRVS’s price has moved between $2.54 and $10.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 8.47% annually for the last half of the decade. The company achieved an average annual earnings per share of 63.89%. With a float of $54.56 million, this company’s outstanding shares have now reached $74.51 million.
In an organization with 31 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Corvus Pharmaceuticals Inc (CRVS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Corvus Pharmaceuticals Inc is 26.78%, while institutional ownership is 30.82%. The most recent insider transaction that took place on Jun 27 ’25, was worth 4,891,894. In this transaction Director of this company sold 1,176,332 shares at a rate of $4.16, taking the stock ownership to the 7,165,006 shares. Before that another transaction happened on Jun 27 ’25, when Company’s Director sold 1,176,332 for $4.16, making the entire transaction worth $4,891,894. This insider now owns 7,165,006 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.6 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.12) by -0.48. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 63.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.99% during the next five years compared to 8.47% growth over the previous five years of trading.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
Corvus Pharmaceuticals Inc (CRVS) is currently performing well based on its current performance indicators. A quick ratio of 8.91 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.02, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.48 million. That was inferior than the volume of 0.82 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.97%.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 72.69%, which indicates a significant increase from 34.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.25 in the past 14 days, which was lower than the 0.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.17, while its 200-day Moving Average is $5.10.
